Search research articles
Contact Us
Filters
Showing results (131-140 of 147) with videos related to
Page
of 15
Sort By:
Gene & Protein in Disease
|
August 1, 2025
Exploring dopamine as the master regulator of brain circuitry and mental health genome
Kenneth Blum, Eric R Braverman, Alireza Sharafshah, et al.
Neurology (E-Cronicon)
|
March 16, 2026
Neurogenetics and Epigenetics of Spirituality and Religion: Seeking Genospirituality Via the Lens of Hierarchical Neuro-Spiritual Model (HNSM)
Kai-Uwe Lewandrowski, Kenneth Blum, Morgan P Lorio, et al.
Psychology Research and Behavior Management
|
December 5, 2023
Neurogenetics and Epigenetics of Loneliness
Abdalla Bowirrat, Igor Elman, Catherine A Dennen, et al.
Neurology (E-Cronicon)
|
September 29, 2025
Multi-Locus Pro-Dopaminergic Restoration of Reward Brain Circuitry in Reward Deficiency Rescinds Mono-Pharmaceutical Targeting
Kenneth Blum, Kavya Mohankumar, Debasis Bagchi, et al.
Frontiers in Public Health
|
October 13, 2025
Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Open Journal of Immunology
|
November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies
Kenneth Blum, Igor Elman, David Han, et al.
Frontiers in Public Health
|
December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Medical Research Archives
|
October 27, 2023
Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
Kenneth Blum, Mark S Gold, Jean Lud Cadet, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 147) with videos related to
Sort By:
Page
of 15
Gene & Protein in Disease
|
August 1, 2025
Exploring dopamine as the master regulator of brain circuitry and mental health genome
Kenneth Blum, Eric R Braverman, Alireza Sharafshah, et al.
Neurology (E-Cronicon)
|
March 16, 2026
Neurogenetics and Epigenetics of Spirituality and Religion: Seeking Genospirituality Via the Lens of Hierarchical Neuro-Spiritual Model (HNSM)
Kai-Uwe Lewandrowski, Kenneth Blum, Morgan P Lorio, et al.
Psychology Research and Behavior Management
|
December 5, 2023
Neurogenetics and Epigenetics of Loneliness
Abdalla Bowirrat, Igor Elman, Catherine A Dennen, et al.
Neurology (E-Cronicon)
|
September 29, 2025
Multi-Locus Pro-Dopaminergic Restoration of Reward Brain Circuitry in Reward Deficiency Rescinds Mono-Pharmaceutical Targeting
Kenneth Blum, Kavya Mohankumar, Debasis Bagchi, et al.
Frontiers in Public Health
|
October 13, 2025
Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Open Journal of Immunology
|
November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies
Kenneth Blum, Igor Elman, David Han, et al.
Frontiers in Public Health
|
December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Medical Research Archives
|
October 27, 2023
Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
Kenneth Blum, Mark S Gold, Jean Lud Cadet, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Page
of 15